Source: InvestorsHub NewsWire
Northvale, NJ -- March 17, 2020 -- InvestorsHub NewsWire -- ADM Tronics Unlimited, Inc. (OTCQB – ADMT) confirms that operations at its research, development, engineering and FDA-registered Medical Device manufacturing facility are currently continuing during the COVID-19 outbreak.
The COVID-19 situation continues to evolve rapidly, locally as well as nationwide and globally. ADMT develops and manufactures diversified products, including medical devices and packaging formulations for foods and pharmaceuticals. ADMT believes many of these technologies will remain in demand during this period and anticipates continued production and operations. ADMT has communicated with its customers and suppliers to confirm operations are continuing.
“We are grateful to our family of employees for their dedication during this difficult time,” stated Andre’ DiMino, ADMT President. “The health of our employees, their families and our community is paramount, so we are exercising caution to help avoid spread of the disease, while at the same time maintaining operations. Products we develop and manufacture are needed for the medical and other industries we serve. We want to maintain our ability to produce these for our loyal customers, and the patients and users needing them."
Here is information about some ADMT customers:
1. Yesterday, Endonovo Therapeutics, Inc., an ADMT customer, announced it is providing SofPulse units for investigational use to evaluate inhibition of inflammatory symptoms associated with COVID-19. SofPulse units are non-invasive, therapeutic medical devices that were developed and are manufactured by ADMT for Endonovo.
2. ADMT received the following statement from Jerry Katzman, MD, “As CEO of SteriView, RetinalGeniX, and Intubation Sciences, to name a few, I am grateful for the success and production schedule that ADM Tronics has been following, and has continued to follow, in developing, R&D testing, and producing our products during these challenging times. Simply put, ADMT has stayed on target in delivering our suite of products and design schedule as needed to meet our requirements to date, and in the months to come.”
3. ADMT has been developing and manufactured for Origin, Inc. the IonoJet™, which allows for targeted delivery of Nitric Oxide ("NO"), produced at the point of therapy from room air, in a thermal plasma. Michael Preston, Chairman and President of Origin, Inc., stated, "Like other nitric oxide companies, we have recognized the potential ability of NO to stop the replication of the corona viruses. We believe there may be fundamental problems with the other approaches we have seen and are working to address these in a novel system that will allow NO to be administered effectively. ADMT has been key to our development and will play an important part in our future.”
4. ADMT is Assisi Animal Health’s development and manufacturing partner for its targeted Pulsed Magnetic Field (tPEMF™) therapeutic devices for the animal healthcare market. L. John Wilkerson, PhD, Assisi’s Chairman, has reached out to distributors, veterinary clinics, and pet owners assuring them that “As we all do our parts in fighting COVID-19, thanks to our long and strong relationship with Andre’ DiMino and the ADM Tronics team, Assisi will be able to continue to supply our customers with the products they rely on to relieve pain and inflammation and to treat anxiety disorders in companion animals.”
You only have to do a very few things right in your life so long as you don't do too many things wrong.
W. Buffett
Recent ADMT News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/20/2024 12:51:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:24:20 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 06/30/2023 06:21:17 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM